SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Infectious Diseases (travel medicine) Consultation — Pierre Le Moyne d'Iberville — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Pierre Le Moyne d'Iberville |
|---|
| Date of birth | 1661-07-16 |
|---|
| Identifiers | MRN HR-ET014-SYN-TD; SSN (made up) 000-14-7260 |
|---|
| Document date | 1705-03-03 |
|---|
| Author | Jean-Baptiste Okonkwo-Hale, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Three episodes of fever with shaking chills and sweats in two years, each beginning months after naval service in malaria-endemic areas, the first called malaria abroad and treated with chloroquine alone, in a 43-year-old naval commander who is afebrile today. Please establish whether these are malaria relapses, advise on antirelapse treatment, and plan his pre-travel care for a deployment to French Guiana and the French Antilles expected early next year. [S]
Urgency: Within two weeks; same day if he develops a fever. [S]
Questions for the consultant:
- Are these relapses of P. vivax (or P. ovale) malaria, and is any further test needed?
- What treatment do you recommend now, given the normal G6PD result?
- What follow-up tests and relapse surveillance are needed?
- Which vaccines, including yellow fever, does he need for French Guiana and the Antilles, and when?
- What malaria chemoprophylaxis and other protection do you advise for the deployment, and is terminal prophylaxis needed on return?
History of Present Illness
Mr. Le Moyne d'Iberville, a 43-year-old naval commander, is seen at the request of Dr. Delacroix-Boateng for recurrent fevers. Over two years he has had three attacks, each about a week of fever with shaking chills every other day, drenching sweats and headache, each beginning months after he left a posting on the Caribbean coast of Central America or the Gulf of Mexico. The first attack was diagnosed as malaria on a smear abroad, species not recorded, and all three were treated with chloroquine alone; he has never taken primaquine or tafenoquine. The last attack ended eight weeks ago and he has had no fever since. He takes no medicines and has no allergies. He is preparing a squadron for a deployment to the French Antilles and French Guiana early next year, with months ashore and possible inland river work. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Pierre Le Moyne d'Iberville was born on July 16, 1661, in Montreal (Ville-Marie), New France, and was baptized there on July 20, 1661. He was the third son of Charles Le Moyne de Longueuil et de Châteauguay and Catherine Thierry. [D]
- The name d'Iberville came from a fief held by his father's family near Dieppe, and d'Ardillières from a property he acquired in Aunis near Rochefort. He was the first person born in Canada to receive the cross of the order of Saint-Louis. [D]
- He fought the English in Hudson Bay and James Bay from 1686: the capture of the James Bay posts in 1686, the Albany River in 1688 to 1689, New Severn in 1690, York Fort (renamed Fort Bourbon) in 1694, and in 1697 the naval battle near York Factory in which his ship, the Pélican, defeated English warships and was itself lost, followed by the surrender of the fort. [D]
- His biographer records that scurvy and exposure killed 25 of the English in the winter of 1688 to 1689 on the Albany River, and that in 1694 at York Fort scurvy killed many men on both sides. [D]
- In 1696 to 1697 he led a campaign against the English: Fort William Henry at Pemaquid capitulated on August 15, 1696, and in Newfoundland St John's surrendered on November 30 after a brief siege; the campaign destroyed 36 settlements, killed about 200 people and took about 700 prisoners. [D]
- He led the expeditions that began the French colony of Louisiana: in April 1699 he chose a site near the entrance of Biloxi Bay, near present-day Ocean Springs, Mississippi, for Fort Maurepas; in 1700 he built a fort on the Mississippi; and on his third voyage he began Fort Saint-Louis at Mobile. He left Louisiana in April 1702 and did not return. [D]
- Sailing from La Rochelle on September 29, 1701, on his third voyage to Louisiana, he was forced by illness to put in at Pensacola. [D]
- His biographer writes that he had attacks of malaria that recurred several times from 1702 to 1705 and that his deteriorating health thwarted planned expeditions to Louisiana; 64 Parishes writes that illness kept him from the expedition of 1703. [D]
- Despite his poor health, he was well enough in 1705 to be entrusted with preparing an armament, and early in 1706 he sailed from France with a squadron of twelve vessels against the English in the West Indies. [D]
- His biographer places the births of three of his children at La Rochelle, in 1698, 1701 and 1705. [D]
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food | 1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total) | Oral route | 1705-03-03 to 1705-03-05 | completed | S |
| Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days | 30 mg base once daily for 14 days | Oral route | 1705-03-03 to 1705-03-16 | completed | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requested | resolved | confirmed |
R50.9 | S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation. |
| Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PD | active | confirmed |
B51.9 | S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic. |
| Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccines | active | confirmed |
Z71.84 | S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705. |
Physical Exam
Vital signs recorded on 1705-03-03; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Well; temperature 36.6 C, blood pressure 122/76, pulse 68 |
| Eyes | Mild conjunctival pallor; no jaundice |
| Abdomen | Spleen tip not palpable; liver not enlarged |
| Skin | No rash |
Assessment
- Relapsing Plasmodium vivax malaria (B51.9). Attacks months after leaving areas where P. vivax predominates, after blood-stage treatment alone, with P. vivax DNA detected between attacks, are relapses from dormant liver stages (hypnozoites). The PCR detects parasites below the threshold of the smear. Mildly low hemoglobin and platelets fit recent attacks. No further diagnostic test is needed. Central American P. vivax is chloroquine-sensitive. With a normal quantitative G6PD, primaquine 30 mg base daily for 14 days is appropriate; at 68 kg that dose meets the total recommended dose. [S]
- Pre-travel care for French Guiana and the French Antilles (Z71.84). French Guiana requires proof of yellow fever vaccination from all arriving travelers, and CDC recommends it; one dose gives long-lasting protection. Hepatitis A, hepatitis B (if not immune) and typhoid vaccines are recommended for a long stay. Malaria is transmitted in parts of French Guiana, mostly P. vivax with some P. falciparum and chloroquine resistance, so chloroquine is not suitable for prophylaxis there. Dengue, chikungunya and rickettsial infections including typhus are prevented by vector avoidance; no dengue vaccine is recommended for travelers. [S]
Data reviewed: Dr. Delacroix-Boateng's intake note and tests: thick and thin smears and rapid antigen test negative; Plasmodium species PCR from the intake sample, reported this week, detected P. vivax DNA; hemoglobin 13.0 g/dL, platelets 141 x10^3/uL, white cells 5.6 x10^3/uL, bilirubin 1.1 mg/dL, ALT 34 U/L, AST 29 U/L, creatinine 0.98 mg/dL, glucose 92 mg/dL; quantitative G6PD activity 11.8 U/g Hb, within the laboratory's normal range. [S]
Plan of Treatment
- Chloroquine 1,000 mg salt now, then 500 mg at 6, 24 and 48 hours, for the blood stage. [S]
- Primaquine 30 mg base daily with food for 14 days for radical cure, starting today; stop and seek care for dark urine, breathlessness or blue lips. [S]
- Blood smear and PCR about a week after the last primaquine dose, with a blood count and bilirubin; then no routine tests, but a smear the same day for any fever. [S]
- Pre-travel vaccines at least a month before departure: yellow fever with the international certificate, hepatitis A, typhoid Vi, and hepatitis B if the screening panel shows he is not immune; influenza in the autumn. [S]
- Atovaquone-proguanil chemoprophylaxis for the malaria areas, with primaquine terminal prophylaxis for 14 days after leaving them because of prolonged P. vivax exposure. [S]
- Repellent, permethrin-treated clothing, bed nets and screened quarters against mosquitoes, fleas, lice and mites; food and water precautions with standby azithromycin for severe travelers' diarrhea. [S]
- Discussed with Dr. Delacroix-Boateng, who saw him the same day. The diagnosis and plan were explained to Mr. Le Moyne d'Iberville, who agreed and took the first chloroquine dose in clinic. [S]
- Follow-up: Infectious diseases review on request or for any fever; primary care review in four weeks and pre-travel vaccines in the summer. [S]